Abiopharma

Commercial papers interest 2 for the period 23.6.25–21.6.26 is 4.68447%

New Form 424B2 - UBS AG <b>Filed:</b> 2026-06-10 <b>AccNo:</b> 0001839882-26-028703 <b>Size:</b> 954 KB

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-06-10 <b>AccNo:</b> 0001213900-26-067163 <b>Size:</b> 2 MB

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-06-10 <b>AccNo:</b> 0001918704-26-016219 <b>Size:</b> 888 KB

New Form 424B2 - CITIGROUP INC <b>Filed:</b> 2026-06-10 <b>AccNo:</b> 0001918704-26-016218 <b>Size:</b> 627 KB

New Form 424B2 - GOLDMAN SACHS GROUP INC <b>Filed:</b> 2026-06-10 <b>AccNo:</b> 0001193125-26-265288 <b>Size:</b> 1 MB

New Form 424B2 - BARCLAYS BANK PLC <b>Filed:</b> 2026-06-10 <b>AccNo:</b> 0001918704-26-016217 <b>Size:</b> 568 KB

New Form 424B2 - BANK OF NOVA SCOTIA <b>Filed:</b> 2026-06-10 <b>AccNo:</b> 0001839882-26-028699 <b>Size:</b> 402 KB

New Form 424B2 - BANK OF AMERICA CORP /DE/ <b>Filed:</b> 2026-06-10 <b>AccNo:</b> 0001918704-26-016216 <b>Size:</b> 1 MB

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region

New Form 424B2 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-06-10 <b>AccNo:</b> 0001918704-26-016215 <b>Size:</b> 903 KB

New Form 424B2 - UBS AG <b>Filed:</b> 2026-06-10 <b>AccNo:</b> 0001839882-26-028698 <b>Size:</b> 930 KB

Coincheck Group Announces Completion of KDDI Strategic Investment

General Announcement: Receipt of the Listing and Quotation Notice from the SGX-ST

New Form 424B3 - JPMORGAN CHASE & CO <b>Filed:</b> 2026-06-10 <b>AccNo:</b> 0001213900-26-067155 <b>Size:</b> 3 MB